PK/PD analyses of circulating tumor DNA (ctDNA) in patients with metastatic colorectal cancer (mCRC) treated with telisotuzumab adizutecan (ABBV-400). This is an ASCO Meeting Abstract from the 2025 ...

The case illustrations demonstrate a wide spectrum of presentation, imaging results and treatment strategies. Debate will continue as to whether lymphocytic hypophysitis is in fact a type of ...

Lymphocytic hypophysitis will continue to be a diagnostic and therapeutic challenge. This fascinating endocrinological disorder requires sophisticated analysis and diagnosis. With careful follow ...

Today, a brief rundown of news involving Intellia Therapeutics and ArriVent BioPharma, as well as updates from Atara Biotherapeutics, Amylyx Pharmaceuticals and InnoCare Pharma that you may have ...

ICP-B02 binds to CD20 on the tumour cells and CD3 on the T cells, redirects and activates T cells to eradicate tumour cells through T-cell Directed Cellular Cytotoxicity (TDCC), which has demonstrated ...

In another Chinese newco out-licensing deal, Innocare Pharma Ltd. and Keymed Biosciences Co. Ltd. out-licensed their co-developed CD20×CD3 bispecific antibody (ICP-B02/CM355) to startup Prolium ...

ICP-B02 binds to CD20 on the tumor cells and CD3 on the T cells, redirects and activates T cells to eradicate tumor cells through T-cell Directed Cellular Cytotoxicity (TDCC), which has demonstrated ...

Investment company RTW Investments has launched a new biotech company called Prolium Bioscience, to advance the development of ICP-B02, a CD20×CD3 bispecific antibody originating from China’s ...

ICP-B02 binds to CD20 on the tumor cells and CD3 on the T cells, redirects and activates T cells to eradicate tumor cells through T-cell Directed Cellular Cytotoxicity (TDCC), which has ...